Price$7.40-0.02 (-0.27%)
01:30 PM07:45 PM
News · 26 weeks28+200%
2025-10-262026-04-19
Mix1390d
- Earnings4(31%)
- Other3(23%)
- Insider3(23%)
- SEC Filings3(23%)
Latest news
25 items- PRPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsPuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour afte
- SECSEC Form PRE 14A filed by Puma Biotechnology IncPRE 14A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, April 1, 202
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Puma Biotechnology IncSCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
- SECSEC Form 10-K filed by Puma Biotechnology Inc10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- SECPuma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
- PRPuma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial ResultsPuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 million in 2024. Based on accounting principles generally accepted in the United State
- PRPuma Biotechnology to Present at TD Cowen's 46th Annual Health Care ConferencePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic
- INSIDERPresident and CEO Auerbach Alan H was granted 159,778 shares, increasing direct ownership by 2% to 7,305,729 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDEROfficer Hunt Douglas M was granted 49,394 shares, increasing direct ownership by 32% to 205,301 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDERChief Financial Officer Nougues Maximo F was granted 46,739 shares, increasing direct ownership by 24% to 240,023 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- PRPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial ResultsPuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortl
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, February 1
- INSIDERPresident and CEO Auerbach Alan H sold $204,878 worth of shares (34,950 units at $5.86), decreasing direct ownership by 0.49% to 7,145,951 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDEROfficer Hunt Douglas M sold $52,696 worth of shares (8,987 units at $5.86), decreasing direct ownership by 5% to 155,907 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- INSIDERChief Financial Officer Nougues Maximo F sold $64,187 worth of shares (10,945 units at $5.86), decreasing direct ownership by 5% to 193,284 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 6, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 10,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, January 1
- SECSEC Form 144 filed by Puma Biotechnology Inc144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
- SECSEC Form 144 filed by Puma Biotechnology Inc144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
- SECSEC Form 144 filed by Puma Biotechnology Inc144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
- PRPuma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday, December 19, 2025. "Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma's continued commercial execution, profitability, and clinical progress," said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. "With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients and shareholders."
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, December 1, 2
- INSIDERDirector Miller Michael Patrick sold $97,228 worth of shares (20,000 units at $4.86), decreasing direct ownership by 27% to 54,000 units (SEC Form 4)4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
- SECSEC Form 144 filed by Puma Biotechnology Inc144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
- PRPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, November 1